Zacks Investment Research
27 Jul 2026, 14:47 UTC · 1h ago
Astrazeneca (AZN) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
27 Jul 2026, 14:47 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
AstraZeneca reported quarterly EPS of $2.63, beating the Zacks Consensus Estimate of $2.50 by 5.2%. — Earnings beats typically trigger positive short-term price action as they signal stronger-than-expected profitability.
+0.40AstraZeneca reported quarterly revenue of $15.38 billion, a 6.4% increase year-over-year. — Steady year-over-year revenue growth demonstrates a positive trajectory in top-line scale and market demand.
+0.30AstraZeneca's reported revenue slightly exceeded the Zacks Consensus Estimate of $15.31 billion by 0.48%. — A marginal revenue beat provides mild validation of growth but is less impactful than the earnings surprise.
+0.10Which stocks this story touches
Continue reading
6 related stories
Top 3 movers · tap to explore
AstraZeneca reported revenue and EPS growth that both beat Zacks Consensus Estimates.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Zacks Investment Research
1h ago
